"Our third quarter performance demonstrates our continued strength and resilience across all three of our businesses. Through the ongoing efforts of our teams around the world, we continue to navigate the dynamic macroeconomic environment and remain focused on delivering transformative healthcare solutions. Looking ahead, I remain confident in our business and ability to continue advancing our innovative portfolio and pipeline."

Worldwide Consumer Health Sales

- Consumer Health worldwide reported sales decreased (0.4%)%, but increased 4.7% operationally¹. Primary operational drivers:
  - Neutrogena
  - Motrin®
  - Aveeno
  - Tylenol
  - Durex

Worldwide Pharmaceutical Sales

- Pharmaceutical worldwide reported sales increased 2.6% or 9.0% operationally¹. Primary operational drivers:
  - Stelara
  - DARZALEX
  - Tremfya
  - Xarelto
  - Invega Sustenna
  - Erelax
  - Upravi

Worldwide MedTech Sales

- MedTech worldwide reported sales increased 2.1% or 8.1% operationally¹. Primary operational drivers:
  - Electrophysiology
  - Contact Lens
  - Wound Closure
  - Tourism
  - Energy
  - Endoscopes
  - Biologics
  - Hips

Note: values may have been rounded; the MedTech segment was previously referred to as the Medical Devices segment.


¹ Non-GAAP financial measures. Non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

² Non-GAAP measures exclude the impact of transactional currency.

³ Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes.